Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and &lt;i&gt;BRAF V600&lt;/i&gt; mutation. The gene discussed is BRAF; the disease is neoplasm.